VRTX - Vertex Pharmaceuticals Inc.

VRTX Stock Chart

VRTX Profile

Vertex Pharmaceuticals Incorporated, a leading biotechnology firm, specializes in the development and commercialization of innovative therapies aimed at treating cystic fibrosis (CF) and other serious diseases. Focused on addressing genetic mutations underlying CF, Vertex markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, tailored for patients with specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Additionally, TRIKAFTA targets CF patients aged 6 years and older with at least one F508del mutation. Vertex's robust pipeline includes VX-864 for Alpha-1 Antitrypsin (AAT) deficiency, VX-147 for APOL1-mediated focal segmental glomerulosclerosis (FSGS), VX-880 for Type 1 Diabetes, VX-548 for acute and neuropathic pain, and CTX001 for severe sickle cell disease (SCD) and beta-thalassemia, all advancing through clinical trials.

Vertex distributes its products primarily through specialty pharmacies and distributors in the United States, with a global reach extending to international specialty distributors, retail chains, hospitals, and clinics. The company's strategic collaborations with industry leaders such as Affinia Therapeutics, CRISPR Therapeutics AG, Moderna, and Merck KGaA underscore its commitment to pioneering genetic therapies and expanding treatment options for patients worldwide. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex Pharmaceuticals continues to drive innovation in biotechnology, advancing therapies that aim to transform the lives of individuals affected by genetic diseases.

The company's research and development efforts are bolstered by partnerships with Arbor Biotechnologies, Kymera Therapeutics, Mammoth Biosciences, Obsidian Therapeutics, and Skyhawk Therapeutics, among others. These collaborations enable Vertex to leverage cutting-edge technologies and scientific expertise in its pursuit of novel treatments for challenging medical conditions. Vertex's comprehensive approach integrates genetic research, clinical development, and global commercialization to meet the diverse needs of patients and healthcare providers worldwide.

With a steadfast commitment to scientific excellence and patient-centric innovation, Vertex Pharmaceuticals remains at the forefront of biotechnology, dedicated to advancing precision medicines that address the underlying causes of genetic diseases. By harnessing the power of genomic insights and therapeutic innovation, Vertex continues to redefine possibilities in healthcare, aiming to improve outcomes and quality of life for patients with serious and life-threatening conditions.

VRTX Revenue Chart

VRTX Earnings

Analyst Ratings